The C1QBP Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the C1QBP gene in HeLa cells, providing a powerful loss-of-function model for dissecting the diverse cellular functions of the C1q-binding protein (C1QBP). This polyclonal population preserves genetic heterogeneity while eliminating C1QBP expression, enabling robust assessment of gene disruption effects without clonal artifacts. The knockout is achieved through targeted CRISPR/Cas9-mediated gene disruption, creating a versatile reagent for studying complement regulation, mitochondrial biology, and apoptosis in a well-characterized human epithelial tumor background.
The host HeLa cell line is an HPV18-positive cervical adenocarcinoma-derived epithelial model that recapitulates key features of HPV-driven transformation. As a classic immortalized tumor line, HeLa cells exhibit deregulated proliferation, altered apoptotic thresholds, and active evasion of immune surveillance, making them an ideal platform to investigate C1QBP??s contributions to cancer cell survival and pathogen interactions. The epithelial origin further supports studies of cell adhesion, migration, and invasion in the context of cervical cancer biology.
C1QBP encodes a multifunctional protein that localizes to both mitochondria and the cell surface. It directly binds the globular heads of C1q, thereby inhibiting activation of the classical complement pathway via C1r, C1s, C4, and C2, and also associates with kininogen and thrombin. Inside mitochondria, C1QBP is an essential component of the mitochondrial ribosome, interacting with MRPL12 and MRPS18 to regulate mitochondrial translation and oxidative phosphorylation. In apoptosis, C1QBP modulates mitochondrial membrane permeability, acting downstream of TNF-alpha, NF-kB, and c-Myc to control cytochrome c release and caspase-3 activation, while engaging Bcl-2 and BAX. It further participates in pathogen recognition by interacting with HIV-1 Rev and HCMV proteins, and integrates signals from LPS and PKC to influence MAP kinase cascades.
In HeLa cells, disruption of C1QBP is particularly relevant for exploring mechanisms of complement evasion, mitochondrial dysfunction, and apoptotic resistance that underlie cervical cancer progression. Given the HPV18-transformed background, this knockout model allows researchers to dissect how C1QBP intersects with oncogenic pathways such as PI3K-AKT and NF-kB signaling, and to evaluate its role in maintaining tumor cell viability under stress. The polyclonal population avoids clonal selection bias, making it suitable for population-level studies of heterogeneous responses in infection, autoimmunity, and drug resistance.
Typical applications include complement hemolytic assays and co-immunoprecipitation to probe C1QBP-C1q interactions, mitochondrial membrane potential and oxygen consumption measurements, apoptosis evaluation via caspase-3/7 activity and TUNEL staining, and migration/invasion assays to assess metastatic potential. The cells also support RT-qPCR and western blotting for validating downstream targets such as Bcl-2 and cytochrome c, and immunofluorescence for subcellular localization studies. This knockout model is a valuable tool for drug target discovery in cervical cancer, infectious disease, and mitochondrial disorders. For additional information or custom applications, please contact Ascent Research.
